Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Lipids ; 2013: 517943, 2013.
Article in English | MEDLINE | ID: mdl-24222859

ABSTRACT

Background. Familial combined hyperlipidemia (FCHL), the most common genetic form of hyperlipdemia, is characterized by a strong familial clustering and by premature coronary heart disease. The FCHL locus has been mapped to human chromosome 1q21-q23. This region includes the retinoid X receptor gamma (RXRG), a nuclear factor member of the RXR superfamily, which plays important roles in lipid homeostasis. Objective. To investigate the possible role of the RXRG gene in the genetic susceptibility to FCHL. Methods. Variations in RXRG gene were searched by direct sequencing, and the identified SNPs were genotyped by PCR-RFLP in 192 FCHL individuals from 74 families and in 119 controls. Results. We identified 5 polymorphisms in the RXRG gene (rs1128977, rs2651860, rs2134095, rs283696, and rs10918169). Genotyping showed that the A-allele of rs283696 SNP was significantly associated with FCHL (corrected P, P c < 0.01). Also the alleles of the rs10918169 and of the rs2651860 SNP were more frequent in FCHL subjects compared to those in controls, although not significantly after correction. When the clinical characteristics of the FCHL subjects were stratified by allele carrier status for each SNP, the rs2651860 SNP was significantly associated with increased levels of LDL-cholesterol and of Apo-B in T-allele carriers (P < 0.04). Finally, haplotypes analysis with all 5 SNPs confirmed the significant association of RXRG gene with FCHL. Specifically, the haplotype containing all 3 "at-risk" alleles, significantly associated with FCHL (A-allele of rs283696, G-allele of rs10918169, and T-allele of rs2651860), showed an OR (Odds Ratio) of 2.02, P c < 0.048. Conversely, the haplotype without all these 3 alleles was associated with a reduced risk for FCHL (OR = 0.39, P c < 0.023). The "at-risk" haplotype CTTAG was also associated with higher LDL-C (P < 0.015). In conclusion, variation in the RXRG gene may contribute to the genetic dyslipidemia in FCHL subjects.

2.
Atherosclerosis ; 213(1): 206-11, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20832801

ABSTRACT

OBJECTIVE: Familial combined hyperlipidemia (FCHL) has been associated with abnormalities in fatty acid metabolism. The adipose triglyceride lipase (PNPLA2) plays a pivotal role in the turnover of fatty acids in adipose tissue and liver. This study was designed to evaluate whether selected PNPLA2 variants may influence the susceptibility to FCHL or its lipid-related traits. METHODS: Four SNPs within the PNPLA2 gene (rs7925131, rs7942159, rs66460720 and the nonsynonymous P481L) were selected based on previous association with decreased plasma levels of free fatty acids (FFA) and total triglycerides (TG) and their high frequency (MAF>0.25). These SNPs were genotyped in 214 FCHL individuals from 83 families and in 103 controls and the corresponding haplotypes were reconstructed. RESULTS: No association between individual SNPs and the FCHL trait was observed. However, two PNPLA2 haplotypes were associated with lower risk of FCHL (P<0.004 after Bonferroni's correction). Compared to the others, these haplotypes were related to lower TG (118.9 ± 66.8 vs. 197.1 ± 114.7 mg/dl; P=0.001) and higher HDL-C (62.3 ± 15.8 vs. 51.0 ± 15.0 mg/dl; P<0.005). In a subgroup of studied subjects (n=63) protective haplotypes were also associated with lower FFA levels (0.33 ± 0.11 vs. 0.46 ± 0.18 mEq/L; P<0.05). These effects were independent from age, BMI and HOMA(IR). CONCLUSION: These data demonstrate that variants within PNPLA2 may modulate the TG component of FCHL trait, thus implicating PNPLA2 as modifier gene in this lipid disorder. They also suggest a potential role of PNPLA2 in the metabolism of TG-rich lipoproteins.


Subject(s)
Genetic Variation , Hyperlipidemia, Familial Combined/blood , Hyperlipidemia, Familial Combined/genetics , Lipase/genetics , Adult , Cohort Studies , Family Health , Fatty Acids/metabolism , Female , Genetic Predisposition to Disease , Haplotypes , Humans , Liver/metabolism , Male , Middle Aged , Polymorphism, Single Nucleotide , Risk
3.
Biochem Biophys Res Commun ; 377(3): 843-6, 2008 Dec 19.
Article in English | MEDLINE | ID: mdl-18952067

ABSTRACT

A subgroup of neutral lipid storage disease has been recently associated with myopathy (NLSDM) and attributed to mutations in the gene (PNPLA2) encoding an adipose triglyceride lipase involved in the degradation of intracellular triglycerides. Five NLSDM patients have been described thus far and we reported three additional patients. A 44-year old Iranian woman and two Italian brothers, aged 40 and 35, presented with exercise intolerance and proximal limb weakness, elevated CK levels, and Jordan's anomaly. Muscle biopsies showed marked neutral lipid accumulation in all patients. The 10 exons and the intron-exon junctions of the PNPLA2 gene were sequenced. Two novel homozygous mutations in exon 5 of PNPLA2 gene were found (c.695delT and c.542delAC). Both mutations resulted in frameshifts leading to premature stop codons (p.L255X and p.I212X, respectively). These mutations predict a truncated PNPLA2 protein lacking the C-terminal hydrophobic domain. These findings indicate that NLSDM is rare, but genetically heterogeneous.


Subject(s)
Frameshift Mutation , Lipase/genetics , Lysosomal Storage Diseases, Nervous System/genetics , Muscular Diseases/genetics , Adult , Biopsy , Exons/genetics , Female , Humans , Lipase/metabolism , Lysosomal Storage Diseases, Nervous System/metabolism , Lysosomal Storage Diseases, Nervous System/pathology , Male , Middle Aged , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscular Diseases/metabolism , Muscular Diseases/pathology
4.
J Mol Cell Cardiol ; 41(6): 934-48, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17020763

ABSTRACT

Gene expression profiling by microarray technologies has been successfully applied to study the transcriptional changes that occur in tissues such as heart, vessels and blood cells in different cardiovascular disorders. Such studies have been performed in human cardiovascular syndromes and in animal models with the aim of unraveling the complex molecular pictures underlying human pathophysiology. As already observed in cancer research, gene expression studies in humans may provide a finer molecular classification of patients with cardiovascular diseases and indicate new markers useful for prognostic and therapeutic strategies. In this paper, we present the findings obtained with microarray platforms to explore transcriptome alterations in cardiovascular diseases. To describe the potential of global expression profiling approach in this field, we have chosen to review the genomic findings obtained in some classic heart diseases with genetic transmission such as hyperthrophic cardiomyopathy and Fabry disease, together with findings obtained in common multifactorial cardiovascular disorders such as heart failure, atherosclerosis and infarction. Wherever feasible, we present the results obtained in patients together with those obtained in the corresponding animal and cellular models.


Subject(s)
Cardiovascular Diseases/genetics , Gene Expression Profiling , Animals , Atherosclerosis/genetics , Cardiovascular Diseases/etiology , Data Interpretation, Statistical , Databases, Genetic , Heart Failure/genetics , Humans , Myocardial Infarction/genetics , Myocardial Ischemia/genetics , Myocarditis/genetics , Oligonucleotide Array Sequence Analysis , Syndrome
5.
Blood Coagul Fibrinolysis ; 16(2): 97-104, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15741796

ABSTRACT

Platelets play a pivotal role in thrombus formation in patients with coronary artery disease (CAD), since the high shear generated in the presence of severe coronary stenoses can increase platelet reactivity (PR) and trigger thrombogenesis. Several reports have suggested a functional effect of human platelet antigen (HPA)-1 and HPA-2 gene polymorphisms on PR. However, the true determinants of high-shear PR in CAD patients taking their usual medications are still incompletely understood. In 104 patients with stable CAD we analyzed the possible clinical, biochemical and genetic factors affecting high-shear PR, measured by the ex vivo platelet function analyzer (PFA-100) collagen-adenosine diphosphate method. In univariate analysis, a lower PR was associated with decreased plasma von Willebrand factor-ristocetin cofactor activity, increased blood levels of triglycerides, female sex, use of thienopyridines, lower platelet count, and HPA-1b carriership. All variables, except HPA-1b, remained associated with lower PR in multivariate analysis. However, the introduction in the model of the HPA-1 and HPA-2 genotypes as interaction terms led to a significant improvement in the prediction of PR, although the quantitative effect was small (about 3% improvement, P=0.046).Thus, in CAD patients, there seems to be only a mild effect of the platelet glycoprotein HPA-1 and HPA-2 polymorphisms on collagen-adenosine diphosphate-stimulated PR after the effect of well-established clinical and biochemical determinants are considered.


Subject(s)
Antigens, Human Platelet/genetics , Antigens/blood , Coronary Disease/blood , Coronary Disease/genetics , Ristocetin/blood , Adenosine Diphosphate/analysis , Aged , Collagen/analysis , Coronary Disease/physiopathology , Humans , Middle Aged , Placental Function Tests , Platelet Activation/genetics , Prognosis , von Willebrand Factor/immunology
6.
Biochem Biophys Res Commun ; 309(2): 391-8, 2003 Sep 19.
Article in English | MEDLINE | ID: mdl-12951062

ABSTRACT

About 10% of cases of hypertrophic cardiomyopathy (HCM) evolve into dilated cardiomyopathy (DCM) with unknown causes. We studied 11 unrelated patients (pts) with HCM who progressed to DCM (group A) and 11 who showed "typical" HCM (group B). Mutational analysis of the beta-myosin heavy chain (MYH7), myosin-binding protein C (MYBPC3), and cardiac troponin T (TNNT2) genes demonstrated eight mutations affecting MYH7 or MYBPC3 gene, five of which were new mutations. In group A-pts, the first new mutation occurred in the myosin head-rod junction and the second occurred in the light chain-binding site. The third new mutation leads to a MYBPC3 lacking titin and myosin binding sites. In group B, two pts with severe HCM carried two homozygous MYBPC3 mutations and one with moderate hypertrophy was a compound heterozygous for MYBPC3 gene. We identified five unreported mutations, potentially "malignant" defects as for the associated phenotypes, but no specific mutations of HCM/DCM.


Subject(s)
Cardiomyopathy, Dilated/classification , Cardiomyopathy, Dilated/genetics , Cardiomyopathy, Hypertrophic, Familial/classification , Cardiomyopathy, Hypertrophic, Familial/genetics , DNA Mutational Analysis/methods , Genetic Predisposition to Disease/genetics , Muscle Proteins/genetics , Adult , Aged , Amino Acid Sequence , Cardiomyopathy, Dilated/diagnosis , Cardiomyopathy, Hypertrophic, Familial/diagnosis , Carrier Proteins/blood , Carrier Proteins/genetics , Carrier Proteins/metabolism , Female , Homozygote , Humans , Male , Middle Aged , Molecular Sequence Data , Muscle Proteins/metabolism , Mutation , Sequence Alignment , Sequence Analysis, Protein , Troponin T/blood , Troponin T/genetics , Troponin T/metabolism , Ventricular Myosins/blood , Ventricular Myosins/genetics , Ventricular Myosins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...